ZA200003927B - 1,2,4,5-tetrahydro-benzo[d]jazepines. - Google Patents

1,2,4,5-tetrahydro-benzo[d]jazepines.

Info

Publication number: ZA200003927B
Authority: ZA; South Africa
Prior art keywords: jazepines; benzo; tetrahydro
Prior art date: 1999-08-06

Application number

ZA200003927A

Other languages

English (en)

Inventor

Geo Adam

Alfred Binggeli

Hans-Peter Maerki

Vincent Mutel

Maurice Wilhelm

Wolfgang Wostl

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-08-02

Publication date

2001-02-06

2000-08-02 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2001-02-06 Publication of ZA200003927B publication Critical patent/ZA200003927B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

ZA200003927A 1999-08-06 2000-08-02 1,2,4,5-tetrahydro-benzo[d]jazepines. ZA200003927B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99115557		1999-08-06

Publications (1)

Publication Number	Publication Date
ZA200003927B true ZA200003927B (en)	2001-02-06

Family

ID=8238742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200003927A ZA200003927B (en)	1999-08-06	2000-08-02	1,2,4,5-tetrahydro-benzo[d]jazepines.

Country Status (27)

Country	Link
US (1)	US6218385B1 (fr)
JP (1)	JP3260350B2 (fr)
KR (1)	KR100390116B1 (fr)
CN (1)	CN1146455C (fr)
AR (1)	AR025035A1 (fr)
AT (1)	ATE254614T1 (fr)
AU (1)	AU774485B2 (fr)
BR (1)	BR0003375A (fr)
CA (1)	CA2314798A1 (fr)
CO (1)	CO5180625A1 (fr)
DE (1)	DE60006618T2 (fr)
ES (1)	ES2209728T3 (fr)
HR (1)	HRP20000520A2 (fr)
HU (1)	HUP0003112A3 (fr)
ID (1)	ID26743A (fr)
IL (1)	IL137688A0 (fr)
MA (1)	MA26748A1 (fr)
NO (1)	NO20003966L (fr)
NZ (1)	NZ506096A (fr)
PE (1)	PE20010467A1 (fr)
PL (1)	PL341890A1 (fr)
RU (1)	RU2240317C2 (fr)
SG (1)	SG93251A1 (fr)
TR (1)	TR200002298A2 (fr)
UY (1)	UY26276A1 (fr)
YU (1)	YU49700A (fr)
ZA (1)	ZA200003927B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002051418A1 (fr) *	2000-12-22	2002-07-04	F. Hoffmann-La Roche Ag	Tetrahydro-(benzo ou thieno)-azepine-pyrazine et derives de triazine en tant qu'antagonistes de mglur 1
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
CA2509413C (fr)	2002-12-20	2012-05-01	Glaxo Group Limited	Derivatifs de benzazepine pour le traitement de troubles neurologiques
EP1633720A1 (fr) *	2003-06-17	2006-03-15	Arena Pharmaceuticals, Inc.	Derives de benzazepine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht2c
EP2332921B1 (fr) *	2003-06-17	2016-03-02	Arena Pharmaceuticals, Inc.	8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride
US20080009478A1 (en) *	2003-10-22	2008-01-10	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20070275949A1 (en) *	2003-10-22	2007-11-29	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
AU2005318959B2 (en)	2004-12-21	2011-12-15	Arena Pharmaceuticals, Inc.	Crystalline forms of (R)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
EP1833473B1 (fr)	2004-12-23	2009-09-09	Arena Pharmaceuticals, Inc.	Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
AU2006282896A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP2314289A1 (fr)	2005-10-31	2011-04-27	Braincells, Inc.	Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
SG10201508066VA (en)	2006-04-03	2015-10-29	Arena Pharm Inc	Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
AU2007249435A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 HT receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
EP1873527A1 (fr) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Procédé d'identification des modulateurs CRMP
EP2068872A1 (fr)	2006-09-08	2009-06-17	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
SI2083811T1 (sl)	2006-11-22	2017-02-28	Clinical Research Associates, Llc	Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma
CN101547892B (zh) *	2006-12-05	2014-08-20	艾尼纳制药公司	制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
TW200845978A (en) *	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8822727B2 (en)	2008-03-04	2014-09-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2010148207A2 (fr)	2009-06-18	2010-12-23	Arena Pharmaceuticals, Inc.	Procédés pour la préparation d'agonistes du récepteur 5-ht2c
EP2544688B1 (fr)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Procédés et compositions pour le traitement du syndrome d'angelman
WO2011150380A1 (fr)	2010-05-28	2011-12-01	Xenoport, Inc.	Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
WO2011153206A1 (fr)	2010-06-02	2011-12-08	Arena Pharmaceuticals, Inc.	Procédés pour la préparation d'agonistes du récepteur 5-ht2c
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR20180094131A (ko)	2010-09-01	2018-08-22	에자이 알앤드디 매니지먼트 가부시키가이샤	신장 손상을 갖는 개체에 대한 로카세린의 투여
US20130315994A1 (en)	2010-09-01	2013-11-28	Zezhi Jesse Shao	Modified-release dosage forms of 5-ht2c agonists useful for weight management
WO2012030938A1 (fr)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Sels de lorcasérine dotés d'acides optiquement actifs
EP2611433A2 (fr)	2010-09-01	2013-07-10	Arena Pharmaceuticals, Inc.	Sels non hygroscopiques d'agonistes de 5-ht2c
UY34436A (es)	2012-10-09	2014-07-31	Arena Pharm Inc	Metodo de control del peso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
WO1992007844A1 (fr) *	1990-11-06	1992-05-14	Pfizer Inc.	Derives de quinazolines utiles pour stimuler l'activite antitumorale
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) *	1993-09-24	1997-05-29	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

2000
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-08-01 CA CA002314798A patent/CA2314798A1/fr not_active Abandoned
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 TR TR2000/02298A patent/TR200002298A2/xx unknown
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2001089472A (ja)	2001-04-03
UY26276A1 (es)	2000-10-31
JP3260350B2 (ja)	2002-02-25
ATE254614T1 (de)	2003-12-15
YU49700A (sh)	2003-04-30
NZ506096A (en)	2002-08-28
BR0003375A (pt)	2001-03-13
RU2240317C2 (ru)	2004-11-20
AR025035A1 (es)	2002-11-06
HUP0003112A3 (en)	2003-07-28
ES2209728T3 (es)	2004-07-01
HU0003112D0 (en)	2000-10-28
NO20003966D0 (no)	2000-08-04
DE60006618D1 (de)	2003-12-24
KR20010082510A (ko)	2001-08-30
PE20010467A1 (es)	2001-04-17
AU774485B2 (en)	2004-07-01
DE60006618T2 (de)	2004-09-23
HRP20000520A2 (en)	2001-06-30
CA2314798A1 (fr)	2001-02-06
HUP0003112A2 (hu)	2002-11-28
KR100390116B1 (ko)	2003-07-04
ID26743A (id)	2001-02-08
SG93251A1 (en)	2002-12-17
IL137688A0 (en)	2001-10-31
CN1283623A (zh)	2001-02-14
TR200002298A3 (tr)	2001-03-21
US6218385B1 (en)	2001-04-17
PL341890A1 (en)	2001-02-12
TR200002298A2 (tr)	2001-03-21
MA26748A1 (fr)	2004-12-20
CO5180625A1 (es)	2002-07-30
NO20003966L (no)	2001-02-07
AU4897900A (en)	2001-02-08
CN1146455C (zh)	2004-04-21

Publication	Publication Date	Title
ZA200003927B (en)	2001-02-06	1,2,4,5-tetrahydro-benzo[d]jazepines.
MXPA01013362A (es)	2003-09-04	Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
MXPA02001088A (es)	2003-09-22	2-pirazolin-5-onas..
EG24361A (en)	2009-03-04	4-pyrimiding1-n-acy1.l.phenlalanines
ZA200202537B (en)	2003-09-23	Pour-on-formulations.
ZA200201829B (en)	2003-08-27	New phenylpiperazines.
ZA200203762B (en)	2004-01-28	4-pyridinyl-IN-acyl-L-phenylalanines.
GB2357283B (en)	2003-09-24	I.S. Machine
ZA200108481B (en)	2003-03-26	8A- and 9A-15-membered lactams.
MXPA02000261A (es)	2003-08-20	Aminoindanos novedosos.
GB2347421B (en)	2002-11-13	I.S. machine
GB2357285B (en)	2003-07-30	I.S. machine
ZA200204581B (en)	2003-08-27	Nitro-sulfobenzamides.
IL146124A0 (en)	2002-07-25	1,5-benzodiazepine derivatives
HUP9902291A2 (hu)	2001-12-28	Új 2,3-benzodiazepin-származékok
GB2347419B (en)	2002-12-18	I.S. machine
ZA200107384B (en)	2002-09-18	Spinneret.
AU3196000A (en)	2000-10-04	3,3'-diketotrehalose
HUP0203381A3 (en)	2003-04-28	5-halo-4-fluoro-4,7,7-trimethyl-3-oxabicyclo[4.1.0]heptane-2-on
GB2350361B (en)	2003-12-03	3,4,5-tricyanophenyl derivatives
GB2349384B (en)	2003-01-15	I.S. machine
GB9910366D0 (en)	1999-06-30	1,5-Benzodiazepine Derivatives
MXPA01011292A (es)	2003-07-14	2,2-dioxidos de 2,1-bencisotiazolina.
EG23327A (en)	2004-12-29	Metraplant "iucd".
IL165436A0 (en)	2006-01-15	7,10-bis-trichlotoacetyl-10 deactylbaccatin III